Cann GroupASX:CAN +150.00% Return-on-Tangible-Equity is 335.01% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 896 Drug Manufacturers companies, Cann Group ranks better than 92.86% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cann Group's annualized net income for the quarter that ended in Dec. 2025 was A$52.76 Mil. Cann Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$15.75 Mil. Therefore, Cann Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 335.01%.
The historical rank and industry rank for Cann Group's Return-on-Tangible-Equity or its related term are showing as below:
ASX:CAN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -402.58 Med: -30.55 Max: 116.93
Current: 116.93
During the past 9 years, Cann Group's highest Return-on-Tangible-Equity was 116.93%. The lowest was -402.58%. And the median was -30.55%.
ASX:CAN's Return-on-Tangible-Equity is ranked better than 92.86% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.795
vs ASX:CAN: 116.93
Cann Group (ASX:CAN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cann Group Return-on-Tangible-Equity Related Terms
Cann Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Cann Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CAN vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cann Group Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cann Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cann Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 335.01% mean?
Cann Group (ASX:CAN) has a Return-on-Tangible-Equity of 335.01% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cann Group and its competitors. According to the industry distribution chart, Cann Group ranks #64 out of 896 companies in the Drug Manufacturers industry, placing it in the top 7.1%.
Is Cann Group's Return-on-Tangible-Equity too high?
Cann Group's current Return-on-Tangible-Equity is 335.01%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.80. Cann Group's value of 335.01% is 4197.8% above this industry median. Based on the distribution chart, Cann Group ranks #64 out of 896 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cann Group's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #64 out of 896 companies for Return-on-Tangible-Equity. This places Cann Group in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.80. Cann Group's value of 335.01% is 4197.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current Return-on-Tangible-Equity of 335.01% is 4197.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cann Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current Return-on-Tangible-Equity is 335.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 75% below its estimated fair value. The current Return-on-Tangible-Equity is 335.01% and 4197.8% above the Drug Manufacturers industry median of 7.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current Return-on-Tangible-Equity is 335.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CAN has been successfully added to your 